Close Menu

CHICAGO (GenomeWeb) – Results presented at the American Society of Clinical Oncology annual meeting here this week are highlighting the possibility of using immune checkpoint inhibitors as a first-line therapy in advanced or metastatic non-small cell lung cancer (NSCLC), though the molecular features marking the cases that may benefit most from immunotherapy alone or in combination with chemotherapy are still being hammered out.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.